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Introduction: Pre-existing atrial fibrillation (AF) may worsen prognosis in patients admitted to the intensive care
unit (ICU).
Methods: In a cohort study (2005–2011) including all patients with first-time ICU admissions in Denmark
(n=57,110), we compared patients with and without pre-existing AF and estimated absolute risks and relative risks
(RRs) of arterial thromboembolism and death within 30 days and 365 days following admission, using Kaplan-Meier
methods and multivariate regression analyses. We analysed the prognostic impact of AF within strata of patient
age, sex, coexisting cardiac diseases, and ICU therapies.
Results: Among ICU patients, 5065 (9 %) had pre-existing AF. Compared with patients without AF, those with AF
were older (median age 75 vs. 62 years) and had more comorbidity. The risk of arterial thromboembolism was
2.8 % in patients with AF and 2.0 % in non-AF patients at 30 days, and 4.3 % and 2.9 %, respectively, at 365 days.
Corresponding RRs were 1.41 crude and 1.14 (95 % confidence interval [CI] 0.93–1.40) adjusted at 30 days, and
1.50 crude and 1.20 (95 % CI 1.02–1.41) adjusted at 365 days. Thirty-day mortality was 27 % in patients with
pre-existing AF and 16 % in non-AF patients (crude RR 1.67, adjusted RR 1.04, 95 % CI 0.99–1.10). Corresponding
mortality estimates at 365 days were 40.9 % and 25.4 %, respectively (crude RR 1.61, adjusted RR 1.03, 95 % CI
1.00–1.07). In stratified analyses, pre-existing AF increased mortality in ICU patients aged <55 years (adjusted RR at
30 days 1.73, 95 % CI 1.29–2.32; adjusted RR at 365 days 1.34, 95 % CI 1.06–1.69) and in ICU patients treated with
mechanical ventilation (adjusted RR at 30 days 1.12, 95 % CI 1.05–1.20, adjusted RR at 365 days 1.09, 95 % CI:
1.04–1.15). Analyses stratified by sex and coexisting cardiac diseases yielded adjusted RRs close to 1.
Conclusions: In ICU patients, pre-existing AF was associated with modestly increased risk of arterial
thromboembolism when adjusted for the substantially higher age and comorbidity levels in patients with AF,
whereas there was no overall association with mortality. In ICU patients aged <55 years and in those treated with
mechanical ventilation, AF predicted increased mortality.* Correspondence: jacob.gamst@rn.dk
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The overall burden of pre-existing chronic diseases is an
important determinant of prognosis for patients admitted
to the intensive care unit (ICU) [1, 2]. Chronic diseases
are reportedly more prevalent in ICU patients than in the
general population, and with the ageing of the population,
the prevalence of chronic diseases is expected to increase
in coming years [1, 3]. Despite this, the prognostic influ-
ence of individual coexisting diseases in ICU patients
remains poorly investigated.
Atrial fibrillation (AF) is the most common heart
rhythm disorder, affecting 1.0–1.8 % of the adult popula-
tion in western countries [4, 5]. In the general popula-
tion, AF has been associated with substantially increased
risk of mortality, stroke, and heart failure [6–8]. In
patients admitted to the ICU, new-onset AF has been
linked to increased risk of death [9, 10]. To date, evidence
on how, and to what extent, pre-existing AF affects the
prognosis for ICU patients is sparse. Pre-existing AF could
potentially have serious consequences in critically ill pa-
tients. The ability to compensate for haemodynamic alter-
ations during critical illness may be reduced in patients
with AF, and the inflammatory response could increase
the risk of thrombosis formation during ICU stay [11].
These possible complications of AF are likely more pro-
nounced with increased severity of illness during the ICU
admission. Also, on the one hand, as the prognostic
impact of AF increases with advancing age, it is possible
that the effect of AF is influenced by patient age [12, 13].
On the other hand, the potentially detrimental effects of
AF may be modified by effective medications prescribed
for AF, such as anticoagulants and heart rhythm–modulat-
ing drugs.
The prevalence of AF is expected to increase consider-
ably in the coming years with the increasing ageing
population and prevalence of comorbidities, and elderly
patients with comorbidities are increasingly admitted to
the ICU [5, 14, 15]. It is therefore of major importance
to elucidate the prognostic impact of AF in ICU patients
of different ages and in those with and without comor-
bidities. Thus, we conducted a large, population-based
cohort study to examine the effect of pre-existing AF
and associated pharmacotherapy on the risk of arterial
thromboembolism (ATE) and death following ICU ad-
mission. We also sought to investigate whether any
prognostic effect of AF differed according to patient age,
sex, and comorbidity and with regard to the reason for
and treatment during ICU admission.
Methods
This nationwide cohort study was conducted in Denmark,
a nation with approximately 5.6 million inhabitants. The
study was based on prospectively collected data from
medical and administrative databases. Each Danishresident is assigned a unique personal identifying number,
which enables unambiguous crosslinking of public regis-
tries for research purposes. The Danish national health
care system offers unrestricted, tax-funded hospital and
primary care to all its citizens.
Identification of the cohort and ICU data
All adult patients (age 15+ years) with a first-time
ICU admission in Denmark between January 2005 and
December 2011 were included in the cohort. We used the
Danish Intensive Care Database (DID) to identify the
cohort members. The DID maintains data on all ICU
admissions in Denmark from 2005 onward [16]. From the
DID, we also retrieved data on treatment with mechanical
ventilation, non-invasive ventilation, inotropes and/or
vasopressors, and renal replacement therapy during the
index ICU admission. To differentiate between ICU
admissions related to recent surgery and medical ICU
admissions, we obtained data from the Danish National
Patient Register (DNPR) on surgical procedures per-
formed within 7 days preceding the ICU admission. The
DNPR includes all patients admitted to Danish hospitals
since 1977 and holds dates of admission and discharge,
surgical procedure codes, and diagnostic codes [17]. We
assessed surgical procedures as any type of surgery and
specified according to cardiac, abdominal, orthopaedic, or
vascular surgery.
Data on atrial fibrillation
We used the DNPR to identify cohort members with
previously diagnosed AF. We considered diagnoses of
AF assigned during either in-hospital admission or at a
hospital specialist outpatient clinic visit within 5 years
before the index ICU admission. Because AF and atrial
flutter share the same code in the DNPR, we were not
able to distinguish between these arrhythmias. However,
it has been demonstrated that, among patients coded
with AF or atrial flutter in the DNPR, 92–95 % have AF
[18, 19]. Data on pre-admission treatment for AF was
acquired from the Danish Health Service Prescription
Registry, which holds data on all prescriptions dispensed
from all Danish pharmacies [20]. We noted prescrip-
tions for the most frequently used medications for AF
(vitamin K antagonists, aspirin, beta-blockers, non-
dihydropyridine calcium-channel blockers, amiodarone,
and digoxin) [21]. We also included data on statins, which
are both frequently prescribed to individuals with cardio-
vascular disease and associated with favourable prognosis
in ICU patients [22].
Data on potential confounders
To control our estimates for confounding by coexisting
diseases, we retrieved data from the DNPR on diagnoses
from previous hospital contacts (in-hospital admission,
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before ICU admission. For the thromboembolism ana-
lyses, we identified the risk factors included in the
CHA2DS2-VASc score (i.e., congestive heart failure,
hypertension, age, diabetes, prior stroke/transient ischae-
mic attack/thromboembolism, vascular disease, and sex
category), which has been validated for prediction of
stroke in patients with AF [13, 23]. For the mortality
analyses, we included data on the 19 disease categories
in the Charlson comorbidity index, which have been
validated for prediction of hospital and ICU mortality
[24–26]. For the mortality analyses, we further included
diagnoses of valvular heart disease, angina pectoris and
chronic ischaemic heart disease, hypertension, alcohol-
ism, and obesity. To address any imbalances in frailty or
health awareness not accounted for by previously diag-
nosed diseases, we additionally retrieved data from the
National Health Service Register, which includes consul-
tations and procedures provided by primary health care
providers [27], on preventive consultations, social medi-
cine–related consultations, application for reimburse-
ment due to chronic or terminal illness, conversational
therapy, and influenza vaccinations by the general prac-
titioner (GP) within 1 year preceding the index ICU
admission.
Outcomes
The outcomes were ATE and death. We evaluated both
outcomes at 30 days and 365 days following the ICU
admission date. We defined ATE as a diagnosis of
non-haemorrhagic stroke or thrombosis or embolism
in arteries of the extremities, the mesenteric arteries,
or unspecified arteries recorded in the DNPR. The
Civil Registration System provided data on vital status
of the cohort members. This database, which is updated
daily, encompasses all Danish residents since 1968 and
holds information on exact dates of birth, death, and
migration [28].
Statistical analyses
Follow-up began at ICU admission and continued until
1 January 2013. We computed the cumulative risk of
ATE in patients with and without pre-existing AF, ac-
counting for the competing risk of death in the analyses
[29]. To further compare the risk of ATE in patients
with AF with that in non-AF patients, we calculated cu-
mulative risk ratios (CRRs), both crude and adjusted for
prevalence of the risk factors in the CHA2DS2-VASc
score. Both cumulative risks and CRRs were computed
by analysing pseudo values for each observation in a
generalized linear model [30, 31]. Within each of the
cohorts of patients with and without pre-existing AF, we
further investigated the effect of pre-admission use of
vitamin K antagonists and aspirin on the risk of ATE bycomparing users with non-users. Because the DNPR
records all diagnoses assigned during an admission to
the same date, some episodes of ATE may have been
present before the patient was transferred to the ICU if
the ATE and ICU admission occurred during the same
hospital admission. In sensitivity analyses, we therefore
estimated the cumulative risk and CRR of ATE at 30
days and 365 days following ICU admission, considering
only ATE diagnosed at a later hospital admission than
the hospital admission during which the patient was
treated at the ICU.
Using the Kaplan-Meier method, we estimated mortal-
ity risks in patients with pre-existing AF and non-AF
patients and compared these by computing relative risks
(RRs) through generalized linear regression analyses of
pseudo observations [30, 32]. The RRs were presented as
crude estimates and estimates adjusted for age, sex,
comorbidities (the 19 disease categories in the Charlson
comorbidity index, valvular heart disease, angina pec-
toris and chronic ischaemic heart disease, hypertension,
alcoholism, and obesity), and frailty markers as defined
by GP services (preventive consultations, social medicine–
related consultations, reimbursement due to chronic or
terminal illness, conversational therapy, and influenza
vaccinations). To investigate whether any effect of AF was
different across subgroups of ICU patients, we divided the
cohort into three age groups of equal size (15–54, 55–70,
and 71–103 years) and repeated the analyses within each
age group. Further, we conducted the analyses within
strata defined by sex, previously diagnosed myocardial in-
farction and congestive heart failure, use of mechanical
ventilation, non-invasive ventilation, inotropes and vaso-
pressor agents, and renal replacement therapy during the
ICU admission, as well as type of surgery performed in
relation to the ICU admission. To examine to effect of
pre-admission treatment for AF, we assessed absolute risks
and RRs of death in users of statins, vitamin K antagonists,
aspirin, beta-blockers, non-dihydropyridine calcium-
channel blockers, amiodarone, and digoxin as com-
pared with non-users in patients with and without AF
separately.
Statistical analyses were performed using Stata 11.2
software (StataCorp, College Station, TX, USA), including
the user-written st0202 package.
Ethics
The study was approved by the Danish Data Protection
Agency (record number 2009-41-3987). Informed con-
sent was not required for this registry study according to
Danish legislation.
Results
The study included 57,110 ICU patients, of whom 5065
(9 %) had pre-existing AF (Table 1). Follow-up was
Table 1 Characteristics of 57,110 ICU patients with and without pre-existing atrial fibrillation
AF, n (%) No AF, n (%) Total, n (%)
Participants 5065 (8.9) 52,045 (91.1) 57,110 (100.0)
Male 3162 (62.4) 28,851 (55.4) 32,013 (56.1)
Age, yr, median (IQR) 75 (67–81) 62 (47–73) 64 (49–75)
Age groups
15–55 yr 257 (5.1) 18,247 (35.1) 18,504 (32.4)
55–71 yr 1534 (30.3) 17,212 (33.1) 18,746 (32.8)
71–103 yr 3274 (64.6) 16,586 (31.9) 19,860 (34.8)
Comorbid conditions
Prior myocardial infarction 1056 (20.1) 5082 (9.8) 6138 (10.8)
Congestive heart failure 1714 (33.8) 3213 (6.2) 4927 (8.6)
Peripheral artery disease 824 (16.3) 4874 (9.4) 5698 (10.0)
Valvular heart disease 1215 (24.0) 3756 (7.2) 4971 (8.7)
Hypertension 2457 (48.5) 10,997 (21.1) 13,454 (23.6)
Angina pectoris 1506 (29.7) 7690 (14.8) 9196 (16.1)
Chronic ischaemic heart disease 1724 (34.0) 6292 (12.1) 8016 (14.0)
Cerebrovascular disease 1217 (24.0) 6386 (12.3) 7603 (13.3)
Hemiplegia 35 (0.7) 420 (0.8) 455 (0.8)
Transient cerebral ischaemic attack 359 (7.1) 1932 (3.7) 2291 (4.0)
Dementia 109 (2.2) 542 (1.0) 651 (1.1)
Chronic pulmonary disease 1336 (26.4) 7769 (14.9) 9105 (16.0)
Connective tissue disease 360 (7.1) 2294 (4.4) 2654 (4.7)
Moderate to severe liver disease 43 (0.8) 614 (1.2) 657 (1.1)
Mild liver disease 117 (2.3) 1597 (3.1) 1714 (3.0)
Diabetes 830 (16.4) 4748 (9.1) 5578 (9.8)
Diabetes mellitus types 1 and 2 with end-organ damage 522 (10.3) 2673 (5.1) 3195 (5.6)
Moderate to severe renal disease 518 (10.2) 2110 (4.1) 2628 (4.5)
Any tumour 967 (19.1) 8750 (16.8) 9717 (17.0)
Leukaemia 27 (0.5) 330 (0.63) 357 (0.6)
Lymphoma 90 (1.8) 651 (1.3) 741 (1.3)
Metastatic solid tumour 149 (2.9) 1604 (3.1) 1753 (3.1)
AIDS 1 (0.0) 64 (0.1) 65 (0.1)
CHA2DS2-VASc score
0 226 (4.5) 11,608 (22.3) 11,834 (20.7)
1 575 (11.4) 15,704 (30.2) 16,279 (28.5)
2+ 4264 (84.1) 24,733 (47.5) 28,997 (50.8)
Lifestyle-related diagnoses
Alcoholism 221 (4.4) 3155 (6.1) 3376 (5.9)
Obesity 491 (9.7) 2908 (5.6) 3399 (6.0)
Consultations and services at the GPa
Seasonal influenza vaccination 2557 (50.1) 13,510 (26.0) 16,067 (28.1)
Preventive consultation 305 (6.0) 2894 (5.6) 3199 (5.6)
Social medicine–related consultation 646 (12.8) 3773 (7.3) 4419 (7.7)
Conversational therapy 70 (1.4) 1646 (3.2) 1716 (3.0)
Reimbursement for chronic illness 73 (1.4) 621 (1.2) 694 (1.2)
Reimbursement for terminal illness 9 (0.2) 70 (0.1) 79 (0.1)
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Table 1 Characteristics of 57,110 ICU patients with and without pre-existing atrial fibrillation (Continued)
Pre-admission cardiovascular drug useb
Statins 1716 (33.9) 11,031 (21.2) 12,747 (22.3)
Aspirin 1988 (39.3) 10,708 (20.6) 12,696 (22.2)
Vitamin K antagonists 2500 (49.4) 1339 (2.6) 3839 (6.7)
Beta-blockers 2742 (54.1) 9254 (17.8) 11,996 (21.0)
Non-dihydropyridine calcium-channel blockers 360 (7.1) 901 (1.7) 1261 (2.2)
Digoxin 1668 (33.0) 779 (1.5) 2447 (4.3)
Amiodarone 363 (7.2) 115 (0.2) 478 (0.8)
ICU therapy
Mechanical ventilation 2114 (41.7) 18,410 (35.4) 20,524 (36.0)
Non-invasive ventilation 550 (11.0) 3772 (7.3) 4322 (7.6)
Renal replacement therapy 254 (5.0) 1432 (2.8) 1686 (3.0)
Treatment with inotropes or vasopressors 2057 (40.6) 14,987 (28.8) 17,044 (29.8)
Surgery performed 0–7 days before ICU admission
Any surgical procedure 3039 (60.0) 32,160 (61.8) 35,199 (61.6)
Cardiac surgery 1038 (20.5) 6669 (12.8) 7707 (13.5)
Vascular surgery 179 (3.5) 2764 (5.3) 2943 (5.2)
Abdominal surgery 899 (17.8) 9608 (18.5) 10,507 (18.4)
Orthopaedic surgery 237 (4,7) 2594 (5.0) 2831 (5.0)
Non-surgical ICU admission 2026 (40.0) 19,885 (38.2) 21,911 (38.4)
AF atrial fibrillation, IQR interquartile range, GP general practitioner
aWithin 1 year preceding ICU admission
bDefined as reimbursed prescription within 100 days preceding the ICU admission
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appeared). The participants’ characteristics are presented
in Table 1.
Risk of arterial thromboembolism
At 30 days following ICU admission, the cumulative risk
of ATE was 2.8 % (95 % CI 2.4–3.3 %) in patients with
pre-existing AF and 2.0 % (95 % CI 1.9–2.2 %) in
patients without AF (Table 2). The corresponding CRR
adjusted for prevalence of the risk factors included in
the CHA2DS2-VASc score was 1.14 (95 % CI 0.93–1.40).
Risks of ATE at 365 days were 4.3 % (95 % CI 3.7–4.4 %)
and 2.9 % (95 % CI 2.7–3.0 %) for patients with and
without pre-existing AF, respectively, with a confounder-
adjusted CRR of 1.20 (95 % CI 1.02–1.41). Considering
only ATE diagnosed at a later hospital admission than
the hospital admission during which the patient was
treated in the ICU, the 30-day risk of ATE was 0.3 %
(95 % CI 0.1–0.5 %) in patients with pre-existing AF
and 0.2 % (95 % CI 0.2–0.3 %) in patients without AF, with
an adjusted CRR of 0.94 (95 % CI 0.35–2.52), and 365-day
risks were 1.7 % (95 % CI 1.3–2.0 %) and 1.0 % (95 % CI
0.9–1.1 %) for patients with and without pre-existing AF,
respectively, with an adjusted CRR of 1.24 (95 % CI 0.92–
1.67) (Additional file 1: Table S1).In patients with AF who were pre-admission users
of aspirin, the adjusted CRR of ATE was 1.05 (95 %
CI 0.64–1.75) at 30 days and 1.20 (95 % CI 1.02–
1.41) at 365 days following ICU admission compared
with patients with AF who were non-users of aspirin.
Among AF patients, pre-admission use of vitamin K
antagonists was associated with adjusted CRRs of 0.57
(95 % CI 0.26–1.25) at 30 days and 0.76 (95 % CI
0.50–1.16) at 365 days following admission.
Mortality
The 30-day mortality was 26.8 % (95 % CI 25.6 %–28.0 %)
in patients with pre-existing AF and 16.0 % (95 % CI
15.7 %–16.4 %) in patients without AF (Table 3). The
confounder-adjusted RR for 30-day mortality of pa-
tients with and without pre-existing AF was 1.04 (95 % CI
0.99–1.10). In the youngest third of the cohort (ages
15–55 years), increased mortality was observed with
pre-existing AF (adjusted RR 1.73, 95 % CI 1.29–2.32),
whereas pre-existing AF did not increase mortality in the
two older age groups (55–71 years and 71–105 years) after
controlling for confounders (adjusted RR 1.09, 95 % CI
0.96–1.24; adjusted RR 1.04, 95 % CI 0.98–1.10). In those
who received mechanical ventilation during the ICU
admission, AF was associated with increased 30-day
Table 2 Risk of arterial thromboembolism at 30 days and 365 days following ICU admission in patients with and without atrial
fibrillation and by pre-admission use of aspirin and vitamin K antagonists
30-day ATE risk 365-day ATE risk
AF No AF AF No AF
Overall
Cumulative risk, % 2.8 (2.4–3.3) 2.0 (1.9–2.2) 4.3 (3.7–4.9) 2.9 (2.7–3.0)
Cumulative risk ratio
Crude 1.41 (1.19–1.67) 1 (ref) 1.50 (1.31–1.73) 1 (ref)
Adjusteda 1.14 (0.93–1.40) 1 (ref) 1.20 (1.02–1.41) 1 (ref)
Aspirin users
Cumulative risk, %
Non-users 2.5 (2.0–3.1) 2.0 (1.8–2.1) 3.7 (3.1–4.4) 2.7 (2.5–2.8)
Users 3.4 (2.6–4.2) 2.4 (2.1–2.7) 5.1 (4.1–6.1) 3.5 (3.2–3.9)
Cumulative risk ratio
Non-users 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Users, crude 1.35 (0.98–1.86) 1.21 (1.05–1.40) 1.36 (1.05–1.77) 1.31 (1.17–1.47)
Users, adjusteda 1.05 (0.64–1.75) 0.78 (0.65–0.93) 1.13 (0.81–1.59) 0.81 (0.70–0.95)
Vitamin K antagonist users
Cumulative risk, %
Non-users 3.4 (2.7–4.1) 2.0 (1.9–2.2) 4.9 (4.1–5.7) 2.9 (2.7–3.0)
Users 2.4 (1.8–3.0) 1.9 (1.2–2.7) 3.7 (2.9–4.4) 3.1 (2.2–4.0)
Cumulative risk ratio
Non-users 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Users, crude 0.70 (0.50–0.96) 0.95 (0.65–1.39) 0.75 (0.58–0.97) 1.07 (0.79–1.46)
Users, adjusteda 0.57 (0.26–1.25) 0.71 (0.46 -1.12) 0.76 (0.50–1.16) 0.82 (0.58–1.16)
AF atrial fibrillation, ATE arterial thromboembolism
95 % confidence intervals are given in parentheses
aAdjusted for the risk factors included in the CHA2DS2-VASc score (i.e., congestive heart failure, hypertension, age, diabetes, prior stroke, vascular diseases, and
sex category)
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RR 1.12, 95 % CI 1.05–1.20).
At 1 year following ICU admission, the mortality was
40.9 % (95 % CI 40.0–42.3 %) in patients with pre-
existing AF and 25.4 % (95 % CI 25.0–25.8 %) in patients
without AF (Table 3). The corresponding adjusted RR
was 1.03 (95 % CI 1.00–1.07). Similar to the 30-day re-
sults, pre-existing AF was associated with a pronounced
increase in mortality among individuals aged 15–55
years (adjusted RR 1.34, 95 % CI 1.06–1.69), whereas this
was not the case in the older patients. Among patients
receiving mechanical ventilation during the ICU admis-
sion, mortality at 1 year following ICU admission was
increased in patients with AF compared with non-AF
patients (adjusted RR 1.09, 95 % CI 1.04–1.15).
In patients with pre-existing AF, pre-admission users
of vitamin K antagonists had lower 30-day and 1-year
mortality compared with non-users (adjusted RR 0.91,
95 % CI 0.82–1.00; adjusted RR 0.91, 95 % CI 0.85–0.97)
(Table 4). Reduced 30-day mortality in patients with AF
was also seen with user of non-dihydropyridine calcium-channel blockers, but the estimate was rather imprecise
(adjusted RR 0.86, 95 % CI 0.71–1.03), and the effect did
not persist at 1 year of follow-up. Patients with AF using
amiodarone had higher 30-day and 1-year mortality than
non-users (adjusted RR 1.15, 95 % CI 0.98–1.34; adjusted
RR 1.12, 95 % CI 1.01–1.25). Among patients with pre-
existing AF, use of statins, aspirin, beta-blockers, and
digoxin did not seem to influence the mortality at 30 days
or 1 year following ICU admission.
Discussion
This study of 57,110 ICU patients provides novel in-
sights into the role of pre-existing AF on the prognosis
for patients admitted to the ICU. Without confounder
adjustment, our findings show that patients with pre-
existing AF are at substantially higher risk of ATE and
death following ICU admission than are patients without
pre-existing AF. However, much of the excess risk of
ATE and most of the excess risk of death is conveyed by
AF’s being part of a complex that includes advanced age
and a high burden of cardiovascular comorbidity. Of
Table 3 Mortality at 30 days and 365 days following admission in 57,110 adult ICU patients with and without atrial fibrillation
AF, % No AF, % Crude RRa Adjusted RRa,b
30-day mortality
Overall 26.8 (25.6–28.0) 16.0 (15.7–16.4) 1.67 (1.59–1.76) 1.04 (0.99–1.10)
Age
15–54 yr 13.6 (10.0–18.5) 6.1 (5.7–6.4) 2.25 (1.64–3.08) 1.73 (1.29–2.32)
55–70 yr 16.7 (14.9–18.7) 14.6 (14.1–15.1) 1.14 (1.02–1.29) 1.09 (0.96–1.24)
71–105 yr 32.6 (31.0–34.2) 28.5 (27.8–29.2) 1.14 (1.08–1.21) 1.04 (0.98–1.10)
Sex
Female 30.0 (28.0–32.1) 16.7 (16.2–17.2) 1.80 (1.67–1.93) 1.05 (0.97–1.14)
Male 24.9 (23.4–26.4) 15.5 (15.1–16.0) 1.60 (1.50–1.71) 1.04 (0.97–1.12)
Prior myocardial infarction
Not present 26.2 (24.9–27.6) 15.6 (15.3–16.0) 1.68 (1.59–1.77) 1.04 (0.98–1.11)
Present 29.1 (26.4–31.9) 20.0 (18.9–21.1) 1.46 (1.31–1.63) 1.06 (0.93–1.19)
Congestive heart failure
Not present 24.2 (22.8–25.7) 15.3 (15.0–15.6) 1.58 (1.49–1.69) 1.04 (0.97–1.10)
Present 31.9 (29.7–34.1) 27.7 (26.2–29.3) 1.15 (1.05–1.26) 1.08 (0.99–1.18)
Mechanical ventilation
No 24.9 (24.3–25.5) 11.2 (10.9–11.5) 2.10 (1.96–2.26) 1.00 (0.93–1.08)
Yes 31.3 (29.4–33.3) 23.6 (22.1–25.1) 1.26 (1.18–1.35) 1.12 (1.05–1.20)
Renal replacement therapy
No 25.9 (24.7–27.1) 15.3 (15.0–15.6) 1.69 (1.60–1.78) 1.04 (0.98–1.09)
Yes 44.1 (38.2–50.4) 41.7 (39.2–44.3) 1.06 (0.91–1.23) 1.04 (0.88–1.22)
Treatment with inotropes or vasopressors
No 24.3 (22.8–25.9) 12.1 (11.7–12.4) 2.02 (1.88–2.16) 1.02 (0.94–1.09)
Yes 30.4 (28.5–32.4) 25.9 (25.2–26.6) 1.17 (1.09–1.26) 1.08 (1.01–1.16)
Non-invasive ventilation
No 25.2 (24.0–26.5) 14.7 (14.4–15.0) 1.72 (1.63–1.81) 1.06 (1.00–1.12)
Yes 39.6 (35.7–43.9) 33.3 (31.8–34.8) 1.19 (1.06–1.33) 0.98 (0.88–1.10)
Surgery performed, any type
No 36.0 (33.9–38.1) 21.2 (20.6–21.7) 1.70 (1.59–1.81) 0.99 (0.93–1.06)
Yes 20.7 (19.3–22.2) 12.9 (12.5–13.3) 1.60 (1.49–1.73) 1.03 (0.95–1.12)
Cardiac surgery performed
No 31.9 (30.5–33.3) 17.5 (17.1–17.8) 1.82 (1.74–1.92) 1.02 (0.97–1.08)
Yes 7.1 (5.7–8.9) 6.3 (5.7–6.9) 1.13 (0.89–1.44) 0.80 (0.52–1.23)
Abdominal surgery performed
No 26.2 (24.9–27.6) 15.8 (15.5–16.2) 1.65 (1.56–1.75) 1.05 (0.99–1.11)
Yes 29.6 (26.7 -32.7) 16.7 (16.2–17.7) 1.75 (1.56–1.95) 1.02 (0.91 -1.14)
Orthopaedic surgery performed
No 26.5 (25.3–27.7) 16.1 (15.7–16.4) 1.65 (1.57–1.74) 1.05 (1.00–1.11)
Yes 33.3 (27.7–39.7) 15.9 (14.6–17.4) 2.09 (1.71–2.56) 1.03 (0.80–1.31)
Vascular surgery performed
No 27.2 (25.9–28.4) 16.4 (16.0–16.7) 1.66 (1.58–1.75) 1.04 (0.99–1.10)
Yes 16.8 (12.0–23.1) 10.4 (9.3–11.6) 1.61 (1.14–2.28) 0.64 (0.31–1.33)
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Table 3 Mortality at 30 days and 365 days following admission in 57,110 adult ICU patients with and without atrial fibrillation
(Continued)
365-day mortality
Overall 40.9 (40.0–42.3) 25.4 (25.0–25.8) 1.61 (1.55–1.67) 1.03 (1.00–1.07)
Age
15–55 yr 19.9 (15.5–25.3) 9.8 (9.4–10.3) 2.02 (1.57–2.59) 1.34 (1.06–1.69)
55–71 yr 28.0 (25.8–30.3) 24.8 (24.2–25.5) 1.13 (1.04–1.23) 1.07 (0.98–1.16)
71–105 yr 48.6 (46.9–50.4) 43.1 (42.4–43.9) 1.13 (1.08–1.17) 1.03 (1.00–1.07)
Sex
Female 45.6 (43.4–48.9) 25.9 (25.4–26.5) 1.76 (1.67–1.86) 1.07 (1.01–1.13)
Male 38.1 (36.4–39.8) 25.0 (24.5–25.5) 1.53 (1.45–1.60) 1.01 (0.96–1.05)
Prior myocardial infarction
Not present 39.9 (38.4–41.5) 24.8 (24.4–25.2) 1.61 (1.55–1.68) 1.02 (0.98–1.07)
Present 44.7 (41.8–47.8) 31.2 (29.9–32.5) 1.43 (1.33–1.55) 1.07 (0.99–1.16)
Congestive heart failure
Not present 37.1 (35.5–38.8) 24.2 (23.8–24.6) 1.53 (1.46–1.61) 1.04 (0.99–1.08)
Present 48.4 (46.0––50.7) 43.8 (42.1–45.6) 1.10 (1.04–1.18) 1.04 (0.98–1.10)
Mechanical ventilation
No 38.8 (38.1–41.6) 21.1 (20.6–21.5) 1.89 (1.80–1.99) 1.00 (0.95–1.05)
Yes 42.4 (40.4–44.6) 33.3 (32.6–34.0) 1.27 (1.21–1.34) 1.09 (1.04–1.15)
Renal replacement therapy
No 39.6 (38.3–41.0) 24.4 (24.1–24.8) 1.62 (1.56–1.68) 1.03 (0.99–1.06)
Yes 63.4 (59.5–71.2) 59.2 (56.6–61.7) 1.10 (1.00–1.22) 1.04 (0.94–1.15)
Treatment with inotropes or vasopressors
No 46.6 (39.2–54.6) 28.7 (26.4–31.2) 1.62 (1.35–1.95) 1.00 (0.82–1.21)
Yes 52.3 (45.1–60.0) 42.9 (40.3–45.6) 1.22 (1.04–1.43) 0.96 (0.82–1.12)
Non-invasive ventilation
No 47.6 (41.6–54.0) 32.2 (30.3–34.3) 1.48 (1.28–1.71) 0.99 (0.85–1.15)
Yes 55.3 (45.1–66.0) 48.6 (44.6–52.7) 1.14 (0.92–1.40) 0.96 (0.78–1.18)
Surgery performed, any type
No 50.1 (47.9–52.3) 30.6 (30.0–31.3) 1.64 (1.56–1.72) 0.96 (0.92–1.01)
Yes 34.8 (33.1–36.5) 22.2 (21.7–22.6) 1.57 (1.49–1.66) 1.07 (1.02–1.13)
Cardiac surgery performed
No 47.6 (46.1–49.2) 27.6 (27.2–28.1) 1.72 (1.66–1.79) 1.00 (0.97–1.04)
Yes 14.9 (12.9–17.3) 10.2 (9.5–10.9) 1.47 (1.25–1.73) 1.11 (0.88–1.40)
Abdominal surgery performed
No 39.7 (38.3–41.2) 24.7 (24.3–25.1) 1.61 (1.55–1.68) 1.03 (0.99–1.07)
Yes 46.4 (43.2–49.7) 28.6 (27.7–29.5) 1.62 (1.50–1.75) 1.04 (0.97–1.12)
Orthopaedic surgery performed
No 40.3 (38.9–41.7) 25.5 (25.1–25.9) 1.58 (1.52–1.64) 1.03 (0.99–1.07)
Yes 54.4 (48.2–60.9) 24.1 (22.5–25.8) 2.27 (1.98–2.59) 1.11 (0.97–1.27)
Vascular surgery performed
No 41.2 (39.8–42.6) 25.8 (25.4–26.2) 1.60 (1.54–1.66) 1.02 (0.99–1.06)
Yes 33.0 (26.6–40.4) 18.0 (16.6–19.5) 1.83 (1.47–2.29) 1.18 (0.88 -1.57)
AF atrial fibrillation, RR relative risk
95 % confidence intervals are given in parentheses
aReference group was non-AF patients within each stratum
bAdjusted for age and sex, comorbidities, and consultations and services provided by the general practitioner
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Table 4 Mortality at 30 days and 365 days following admission in 57,110 adult ICU patients with and without pre-admission use of
different drugs, according to atrial fibrillation status
Users, % Non-users, % Crude RRa Adjusted RRa,b
30-day mortality
Statins
No AF 15.8 (15.1–16.5) 16.1 (15.8–16.5) 0.98 (0.93–1.03) 0.83 (0.79–0.88)
AF 23.6 (21.7–25.7) 28.4 (26.9–30.0) 0.83 (0.75–0.92) 0.93 (0.84–1.04)
Aspirin
No AF 20.1 (19.3–20.8) 15.0 (14.7–15.4) 1.34 (1.28–1.40) 0.93 (0.88–0.97)
AF 28.2 (26.3–30.3) 25.9 (24.4–27.5) 1.09 (0.99–1.20) 0.99 (0.91–1.09)
Vitamin K antagonists
No AF 23.3 (21.1–25.7) 15.9 (15.5–1.62) 1.47 (1.33–1.62) 1.07 (0.97–1.19)
AF 22.9 (21.3–24.6) 30.6 (28.9–32.4) 0.75 (0.68–0.82) 0.91 (0.82–1.00)
Beta-blockers
No AF 17.2 (16.4–17.9) 15.8 (15.4–16.1) 1.09 (1.02–1.12) 0.91 (0.86–0.95)
AF 26.4 (24.8–28.1) 27.3 (25.5–29.2) 0.97 (0.88–1.06) 1.07 (0.98–1.18)
Non-dihydropyridine CCBs
No AF 21.4 (18.9–24.3) 16.0 (15.6–16.3) 1.34 (1.18–1.52) 1.04 (0.92–1.17)
AF 24.2 (20.1–28.9) 27.0 (25.8–28.3) 0.90 (0.74–1.08) 0.86 (0.71–1.03)
Digoxin
No AF 32.7 (29.6–36.2) 15.8 (15.5–16.1) 2.07 (1.87–2.30) 1.15 (1.03–1.28)
AF 29.5 (27.4–31.8) 25.5 (24.0–27.0) 1.16 (1.05–1.27) 0.97 (0.88–1.07)
Amiodarone
No AF 25.2 (18.3–34.2) 16.0 (15.7–16.3) 1.58 (1.15–2.16) 1.08 (0.83–1.42)
AF 27.3 (23.0–32.2) 26.8 (25.5 -28.0) 1.02 (0.86–1.21) 1.15 (0.98 -1.34)
365-day mortality
Statins
No AF 24.8 (24.0–25.6) 25.6 (25.1–26.0) 0.97 (0.94–1.01) 0.82 (0.79–0.86)
AF 36.7 (34.5–39.1) 43.1 (41.4–44.8) 0.85 (0.79–0.92) 0.95 (0.88–1.02)
Aspirin
No AF 31.0 (30.2–31.9) 23.9 (23.5–24.4) 1.30 (1.25–1.34) 0.93 (0.90–0.96)
AF 42.7 (40.6–44.9) 39.8 (38.1–41.5) 1.07 (1.00–1.15) 1.00 (0.94–1.06)
Vitamin K antagonists
No AF 37.8 (35.3–40.5) 25.1 (24.7–25.5) 1.51 (1.41–1.62) 1.11 (1.03–1.19)
AF 35.4 (33.5–37.3) 46.3 (44.4–48.3) 0.76 (0.71–0.82) 0.91 (0.85–0.97)
Beta-blockers
No AF 26.9 (26.0–27.7) 25.1 (24.6–25.5) 1.07 (1.03–1.11) 0.89 (0.86–0.93)
AF 39.4 (37.6–41.3) 42.7 (40.7–44.8) 0.92 (0.86–0.99) 1.00 (0.95–1.07)
Non-dihydropyridine CCBs
No AF 33.3 (30.3–36.5) 25.3 (24.8–25.6) 1.32 (1.20–1.45) 1.02 (0.94–1.11)
AF 39.4 (34.6–44.7) 41.0 (39.6–42.4) 0.96 (0.84–1.10) 0.93 (0.82–1.05)
Digoxin
No AF 50.1 (46.6–53.6) 25.0 (24.7–25.4) 2.00 (1.86–2.15) 1.16 (1.08–1.24)
AF 45.0 (42.6 -47.4) 38.9 (37.3–40.6) 1.15 (1.08–1.24) 1.01 (0.95–1.08)
Gamst et al. Critical Care  (2015) 19:299 Page 9 of 12
Table 4 Mortality at 30 days and 365 days following admission in 57,110 adult ICU patients with and without pre-admission use of
different drugs, according to atrial fibrillation status (Continued)
Amiodarone
No AF 44.4 (35.8–53.9) 25.4 (25.0–25.7) 1.75 (1.42–2.15) 1.18 (0.99–1.41)
AF 42.2 (37.3–47.4) 40.8 (39.4–42.2) 1.03 (0.91–1.17) 1.12 (1.01–1.25)
AF atrial fibrillation, RR relative risk, CCBs calcium channel blockers
95% confidence intervals are given in parentheses
aReference group was non-users within each stratum
bAdjusted for age and sex, comorbidities, and consultations and services by the general practitioner
Gamst et al. Critical Care  (2015) 19:299 Page 10 of 12note, AF per se appeared to increase mortality in youn-
ger ICU patients and in those treated with mechanical
ventilation. In patients with pre-existing AF, pre-
admission users of vitamin K antagonists seemed to have
a lower risk of ATE and had reduced mortality.
Biological mechanisms behind these findings cannot
be clarified by this observational study. AF is a well-
established risk factor for development of thrombo-
embolic events [7]. In the general population, the stroke
risk associated with AF is dependent on coexisting
diseases, as expressed by the CHA2DS2-VASc score
[13, 23]. In our cohort, AF was associated with a
modestly increased risk of ATE even after we adjusted
for the risk factors included in the CHA2DS2-VASc
score, indicating that patients with pre-existing AF
are more vulnerable to the mechanisms leading to in-
creased risk of ATE in critical illness than are non-
AF patients. These mechanisms may include increased
procoagulant activity induced by the inflammatory re-
sponse [33]. Frailty following critical illness could also
be an explanation of the increased long-term risk of
ATE. Even though our results did not unambiguously
demonstrate reduced risk of ATE with pre-admission use
of vitamin K antagonists, patients with AF who were vita-
min K antagonist users had lower mortality at both 30
days and 1 year following ICU admission, illustrating that
protection from hypercoagulation could be beneficial for
AF patients admitted to the ICU.
In two previous studies, researchers have reported in-
ICU mortality ranging from 25 % to 27 % in patients
with pre-existing AF, which is compatible with our
30-day estimate [34, 35]. The intent of the previous
studies was not to describe the prognostic impact of
pre-existing AF in ICU patients, however, and no RR
estimates were reported. Our finding of no excess
mortality with pre-existing AF contrasts with reports
of increased mortality in ICU patients with new-onset
AF. Perhaps new-onset AF during ICU admission re-
flects greater disease severity rather than being a
cause of increased mortality per se. Alternatively, patients
with pre-existing AF may have adapted to the condi-
tion—physiologically or by use of medications—and could
therefore be less susceptible to complications than ICU
patients with new-onset AF. In ICU patients younger than55 years of age and in those treated with mechanical ven-
tilation, we did find increased mortality with AF. Young
ICU patients have little comorbidity, and their absolute
mortality is comparably low. Thus, on a relative scale,
presence versus absence of AF is likely to impact mortality
more in this age group than in older, multimorbid ICU
patients, in whom the effect of AF is often conjugated
with effects of many other conditions. The 1.12-fold rela-
tive mortality increase with AF in patients treated with
mechanical ventilation may be of clinical relevance, given
the high absolute mortality risk in this patient group.
Tachycardia and irregular heart rate may reduce cardiac
filling in patients with AF, which could be further com-
promised by the positive intrathoracic pressure stemming
from mechanical ventilation. Alternatively, mechanical
ventilation may be mainly a marker of greater disease se-
verity during which pre-existing AF could have an impact
on mortality in patients with severe haemodynamic in-
stability due to diminished cardiac performance caused by
AF itself.
Pre-admission use of beta-blockers and statins has
previously been associated with favourable prognosis in
a broad population of ICU patients [22, 36]. We did not
find a beneficial effect of either statins or beta-blockers
in patients with AF, however. Of note, our estimates in
non-AF patients were comparable with those previously
reported [22, 36].
Strengths and limitations
Major strengths of this study include its population-
based design, that it was conducted within a uniform
health care system, the use of prospectively and inde-
pendently sampled data, and virtually complete follow-
up, thereby reducing the risk of selection problems seen
in studies based on selected clinics or patient groups. AF
is reliably coded in the DNPR with a positive predictive
value in the range 93–99 % [19, 37, 38].
The positive predictive value for ischaemic stroke is
88–100 %. Of patients coded with unspecified stroke,
57–70 % have ischaemic stroke [39, 40]. As previously
noted, we were unable to assess exact temporal relation-
ships between diseases diagnosed during the same admis-
sion, and some cases of ATE may have been present at
ICU admission, thereby overestimating the risk of ATE
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issue in our sensitivity analysis, but the data are likely to
underestimate the true risk of ATE as we considered only
ATE diagnosed after discharge from the entire hospital ad-
mission during which the patient was treated in the ICU.
The use of filled prescriptions as a proxy for use of
pharmaceuticals implies that any non-adherence or dis-
continuation of a given drug before admission would
introduce a bias towards the null. Likewise, as we did
not have data on in-hospital treatments, discontinuation
of a drug during admission could also lead to a down-
ward bias. Indeed, as ICU patients often receive nutri-
tion via a feeding tube, it is likely that many patients in
this cohort have had their pre-admission oral medica-
tions paused or altered. Also, use of anticoagulants, such
as low molecular weight heparins, during the ICU ad-
mission could influence the risks of ATE and death in
patients with AF, but we lacked data to elaboration on
this potential mechanism. Users of prophylactic medica-
tions may in general have greater awareness of own
health and disease than non-users. The structure of the
Danish health care system with tax-funded medical care
and partial reimbursement of prescription drugs prob-
ably outbalances these effects to some extent, and previ-
ous research has shown that users of medications such
as statins in Denmark in fact have an unhealthier life-
style than non-users [41]. Still, we cannot rule out that
our finding of a beneficial effect of pre-admission use of
vitamin K antagonists is affected by a ‘healthy user/
adherer bias’, or rather a ‘frail non-user bias’.
The detailed registries and our large dataset allowed
us to control extensively for potential confounders, of
which the disease categories included in the Charlson
comorbidity index have been validated with a mean posi-
tive predictive value of 98 % [42]. Because there is a sub-
stantial overlap in the disease categories included in the
Charlson comorbidity index and the CHA2DS2-VASc
score, we also expect the coding of the latter to have a
high validity, albeit residual confounding and confounding
from unmeasured variables, such as diseases managed
solely by the patient’s GP (which includes, e.g., uncompli-
cated hypertension and uncomplicated type 2 diabetes)
and lifestyle factors, could still influence our estimates.
Conclusions
Pre-existing AF is common in ICU patients and predicts
increased risk of ATE and death. However, coexisting
diseases and advanced age in patients with AF explain
much of these findings. AF was an independent risk fac-
tor for ATE at 1 year following ICU admission and for
death at 30 days and 1 year following admission in ICU
patients treated with mechanical ventilation and in pa-
tients younger than 55 years of age. Pre-admission use
of vitamin K antagonists improved the prognosis forpatients with AF. At present, there are no standards for
management of pre-existing AF in ICU patients, and this
study highlights the urgent need for evidence-based
clinical guidelines in this area.
Key messages
 This population-based study shows that pre-existing
AF is common in ICU patients and a marker of
increased risk of ATE and death.
 The increased risk of ATE and death is largely
explained by older age and more comorbidities in
patients with AF.
 Pre-existing AF per se predicts increased mortality
in ICU patients younger than 55 years of age and in
ICU patients treated with mechanical ventilation.
 Pre-admission use of vitamin K antagonists
improves the prognosis for ICU patients with
pre-existing AF.
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